News
First adrenal insufficiency patient dosed in Phase II study
Diurnal has announced that the first patient has been dosed in its phase 2 European clinical trial of modified-release hydrocortisone.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Diurnal has announced that the first patient has been dosed in its phase 2 European clinical trial of modified-release hydrocortisone.